Partner With Us
Advertisement
Conexiant chevron_right FDA & Government News

FDA & Government News

thumb description

July 09, 2026

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Conexiant

thumb description

July 08, 2026

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

Conexiant

thumb description

July 07, 2026

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

thumb description

July 07, 2026

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

Conexiant

thumb description

July 07, 2026

Settlement Bars Two From DEA Registration

A DOJ settlement resolved allegations involving a cash-pay pain practice in which continued access to controlled-substance prescriptions was tied to recurring payments.

Conexiant

thumb description

July 06, 2026

FDA Issues CRL for Orviglance NDA

Ascelia Pharma plans to request a Type A meeting with the FDA following receipt of a Complete Response Letter.

Conexiant

thumb description

July 02, 2026

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

Conexiant

thumb description

July 01, 2026

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Conexiant